title: [Childhood-onset myasthenia gravis: the analysis of influencing factors of therapeutic effect and prognosis].
abstract: OBJECTIVE
  Though myasthenia gravis (MG) is a typical autoimmune disorder, there was some controversy on the treatment of the childhood-onset MG. By observing the efficacy of different therapies, the authors analyzed the affecting factors of prognosis in childhood-onset MG.
  
  
  METHODS
  The retrospective data of 155 patients with childhood-onset MG (age of MG onset was less than 15 years) were collected from Department of Neurology, Beijing Tongren Hospital (January 2000 - February 2010). The patients were non-randomly divided according to their treatment into 3 groups (glucocorticoid, thymectomy and glucocorticoid combined with thymectomy groups). Postintervention status meeting the criteria of Myasthenia Gravis Foundation of America (MGFA) "complete stable remission, CSR", "pharmacologic remission, PR", "minimal manifestations, MM", or "Improved, I" was regarded as desirable response, which was used as primary indicator of observation. The authors assessed the efficacy of three therapies and analyzed the influencing factors of prognosis by using Chi-square test and Logistic regression.
  
  
  RESULTS
  At 3 months of treatment, glucocorticoid group showed the highest effective rate. At the end of 1 year or 2 years of treatment, glucocorticoid combined with thymectomy group showed the highest effective rate respectively. The generalization rate of MG at 2 years, 10 years and 20 years in childhood-onset ocular MG patients were 4.3%, 10.7%, and 41.5%, respectively. Of patients with generalization of MG, 48.1% occurred within 2 years, 92.6% within 20 years. Univariate analysis showed that in childhood-onset ocular MG patients, variables such as age at onset (> 10 years), LG-MG and with chronic fatigue were significantly associated with general MG conversion. Whereas multivariate analysis showed that patients with age at onset (> 10 years) and chronic muscle fatigue were apt to convert to generalized MG.
  
  
  CONCLUSIONS
  Glucocorticoid appeared to have an effect that leads to early remission of symptoms in childhood-onset MG patients and glucocorticoid combined with thymectomy appeared to have better long-term effect. For those childhood-onset ocular MG patients with longer course of disease, older age of onset, chronic fatigue, or LG-MG, physicians should try to prevent the generalization of MG by immunosuppressive therapies.
authors.affiliation: Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
authors.forename: Ning-ning
authors.initials: NN
authors.lastname: Qin
authors.forename: Rui-ling
authors.initials: RL
authors.lastname: Chen
authors.forename: Shan
authors.initials: S
authors.lastname: Ma
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Zhang
authors.forename: Hou-liang
authors.initials: HL
authors.lastname: Sun
authors.forename: Yun
authors.initials: Y
authors.lastname: Jing
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D013934:Thymectomy; D055815:Young Adult
chemical_list: D005938:Glucocorticoids